Combining Molecularly Targeted Agents: Is More Always Better?

The concurrent targeting of critical nodes along key signaling pathways with molecularly targeted agents is a rational antitumor strategy, which has had varying degrees of success. Combinatorial challenges include overcoming synergistic toxicities and establishing whether combinations are truly active, to make “go, no-go” decisions to proceed to later phase trials. Clin Cancer Res; 23(5); 1123–5. ©2016 AACR. See related article by Calvo et al., p. 1177

[1]  P. Ascierto,et al.  Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. , 2014, The New England journal of medicine.

[2]  Hans Clevers,et al.  Modeling Development and Disease with Organoids , 2016, Cell.

[3]  U. Banerji,et al.  Are Doses and Schedules of Small-Molecule Targeted Anticancer Drugs Recommended by Phase I Studies Realistic? , 2015, Clinical Cancer Research.

[4]  Keunchil Park,et al.  Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  P. Jänne,et al.  Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial. , 2014, The Lancet. Oncology.

[6]  Roman Rouzier,et al.  Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials , 2015, Journal of the National Cancer Institute.

[7]  G. Scagliotti,et al.  Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  T. Yap,et al.  Development of therapeutic combinations targeting major cancer signaling pathways. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  C. Lovly,et al.  Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade , 2015, Clinical Cancer Research.

[10]  J. Clohessy,et al.  Mouse hospital and co-clinical trial project—from bench to bedside , 2015, Nature Reviews Clinical Oncology.

[11]  M. Hidalgo,et al.  A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors , 2016, Clinical Cancer Research.

[12]  S. Ou,et al.  Dacomitinib in lung cancer: a “lost generation” EGFR tyrosine-kinase inhibitor from a bygone era? , 2015, Drug design, development and therapy.